Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL 2: Phase 2 Study of Infigratinib in Children with Achondroplasia
2019-002954-21Phase 2Completed
- Sponsor
- QED Therapeutics
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infigratinib in achondroplasia (ACH), sponsored by QED Therapeutics. Primary endpoint: Treatment-emergent adverse events leading to dose modification or discontinuation. Started Jan 2020; status: completed.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2019-002954-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002954-21.